Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $22.50 Consensus PT from Analysts

Protara Therapeutics, Inc. (NASDAQ:TARA) has been given a consensus rating of “Buy” by the six research firms that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the stock in the last year is $20.40.

TARA has been the subject of a number of recent research reports. Lifesci Capital began coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 price objective for the company. Scotiabank assumed coverage on Protara Therapeutics in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $12.00 target price for the company. Cantor Fitzgerald started coverage on Protara Therapeutics in a report on Friday, March 14th. They issued an “overweight” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics in a research note on Thursday, March 6th.

Insider Transactions at Protara Therapeutics

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the sale, the insider now owns 98,861 shares of the company’s stock, valued at $447,840.33. The trade was a 17.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. RA Capital Management L.P. lifted its holdings in Protara Therapeutics by 78.9% in the fourth quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock worth $17,952,000 after purchasing an additional 1,500,000 shares during the period. Janus Henderson Group PLC acquired a new stake in Protara Therapeutics in the fourth quarter worth approximately $11,938,000. Adage Capital Partners GP L.L.C. bought a new position in Protara Therapeutics during the 4th quarter valued at $11,880,000. Toronto Dominion Bank acquired a new position in shares of Protara Therapeutics during the 4th quarter valued at $11,030,000. Finally, Blackstone Inc. acquired a new position in shares of Protara Therapeutics during the 4th quarter valued at $8,870,000. 38.13% of the stock is owned by institutional investors and hedge funds.

Protara Therapeutics Stock Up 2.3 %

NASDAQ:TARA opened at $3.94 on Wednesday. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48. The company has a market cap of $144.86 million, a PE ratio of -1.40 and a beta of 1.60. The business’s 50 day moving average is $4.03 and its two-hundred day moving average is $3.94.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.09. As a group, sell-side analysts expect that Protara Therapeutics will post -3.32 EPS for the current fiscal year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.